<DOC>
	<DOCNO>NCT00069940</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Colony-stimulating factor sargramostim increase number immune cell find bone marrow peripheral blood . Combining vaccine therapy sargramostim may cause strong immune response kill tumor cell . PURPOSE : This phase I trial study side effect vaccine therapy give together sargramostim treat patient advanced sarcoma brain tumor .</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim Treating Patients With Sarcoma Brain Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility treatment telomerase : 540-548 peptide vaccine sargramostim ( GM-CSF ) patient sarcoma brain tumor . - Determine safety tolerability regimen patient . - Determine frequency T-cell specific vaccine antigens administration regimen patient . - Determine , preliminarily , clinical response , , patient treat regimen . OUTLINE : Patients receive telomerase : 540-548 peptide vaccine subcutaneously ( SC ) day 3 sargramostim ( GM-CSF ) SC day 1-4 week 1 , 3 , 5 , 7 , 9 , 11 , 15 , 19 , 23 . PROJECTED ACCRUAL : A total 35 patient ( 20 adult 15 pediatric ) accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 follow malignancy : Stage III IV sarcoma , include : Leiomyosarcoma Synovial cell sarcoma Liposarcoma Gastrointestinal stromal tumor Brain tumor , include : Diffuse pontine glioma* Glioblastoma multiforme Glialsarcoma NOTE : *For patient diffuse pontine glioma , requirement histologic verification may waive No known curative therapy HLA A*0201 positive genotyping PATIENT CHARACTERISTICS : Age Over 2 Performance status Karnofsky 60100 % ( patient age 16 ) Lansky 60100 % ( patient age 16 ) Life expectancy Not specify Hematopoietic WBC great 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic AST ALT less 2.5 time upper limit normal ( ULN ) Bilirubin le 1.5 time ULN Renal Creatinine less 1.5 time ULN Cardiovascular No clinically significant cardiovascular disease Pulmonary No clinically significant pulmonary disease PRIOR CONCURRENT THERAPY : Biologic therapy No prior hematopoietic stem cell transplantation No concurrent vaccine therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy Concurrent dexamethasone allow provide patient decrease dose past 2 week current dose low clinically acceptable dose ( ideally , less 912 mg/day ) Radiotherapy No prior extensivefield radiotherapy would compromise bone marrow function At least 2 week since prior local radiotherapy Surgery At least 2 week since prior surgery Other At least 2 week since prior imatinib mesylate No concurrent local anesthetic administration site vaccine</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>childhood synovial sarcoma</keyword>
	<keyword>childhood leiomyosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>childhood liposarcoma</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
</DOC>